First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
PHASE1
This is an open-label, FIH study designed to evaluate the maximum tolerated...
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
PHASE3
This is a a phase III, randomized, open-label clinical trial comparing endo...
Status
Not Yet Recruiting
Location
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University